285 Glioblastoma Clinical Trials Recruiting Now (July 2026): GBM, MGMT, Niraparib, GammaTile, CAR-T

Last updated: July 1, 2026

Answer a few questions to find clinical trials matched to your specific Glioblastoma situation.

Usually 2–3 minutes. No sign-up.

Current Clinical Trial Landscape

Active research areas in mid-2026:

CAR-T cell therapy targeting EGFRvIII (including conditional synNotch designs), IL13Rα2, HER2, GD2, and DLL3
Checkpoint immunotherapy combinations — pembrolizumab, nivolumab, retifanlimab — with TTFields, RT, or anti-angiogenics
Blood-brain barrier opening — Sonocloud-9 ultrasound + carboplatin (Phase 3) and NaviFUS microbubble-mediated focused ultrasound with bevacizumab (Phase 3)
Tumor vaccines — dendritic cell (DOC1021, DCVax-L), neoantigen, peptide, and RNA-based
Tumor treating fields (TTFields/Optune) combinations — EF-41/KEYNOTE-D58 adds pembrolizumab in newly-diagnosed GBM (Phase 3)
Adaptive platform trials — GBM AGILE, INSIGhT — testing multiple agents simultaneously

Standard of care (Stupp protocol, since 2005): Maximal safe resection → concurrent radiation + temozolomide → adjuvant temozolomide. Tumor treating fields (Optune) added for newly diagnosed GBM (EF-14, 2015). MGMT promoter methylation predicts temozolomide benefit. For MGMT-unmethylated tumors, clinical trials are especially important as TMZ benefit is limited. Median overall survival on standard of care remains roughly 14–20 months, which is why trials matter at every stage.

Key Biomarkers for Trial Eligibility

Most GBM trials require specific biomarker information. Knowing your status helps match you to the right trial:

IDH status — Under the WHO 2021 CNS tumor classification, glioblastoma is defined as IDH-wildtype only. What used to be called "IDH-mutant GBM" is now classified as IDH-mutant astrocytoma (grade 4) — a separate disease with different biology and trial eligibility. If your pathology report says IDH-mutant, the trials on this page may not apply; look for astrocytoma- or IDH-mutant-glioma-specific studies (vorasidenib was approved by the FDA in August 2024 for residual or recurrent grade 2 IDH-mutant glioma after surgery — it is not a GBM drug).
MGMT methylation — Methylated (~40%) vs unmethylated (~60%). Unmethylated patients benefit less from temozolomide and are prioritized for novel approaches. Several Phase 3 trials specifically target MGMT-unmethylated newly-diagnosed GBM (NCT06388733, niraparib (Zejula) vs TMZ — first PARP Phase 3 in glioma).
EGFRvIII — Present in ~25-30% of GBM. Target for CAR-T therapies (including synNotch dual-targeting designs) and vaccine approaches.
Newly diagnosed vs recurrent — Very different trial menus. Newly-diagnosed trials add agents to Stupp; recurrent trials test CAR-T, BBB-opening, focused ultrasound, and reirradiation.

Know your biomarkers? Get matched to GBM trials in minutes.

Find Matching Trials

Recruiting Trials by Treatment Setting

Newly Diagnosed GBM — Added to Standard Chemoradiation

Trials adding novel agents to the Stupp protocol (surgery + RT/TMZ). Several Phase 3 trials are open, with new Phase 3 entrants in early 2026:

MGMT-unmethylated focused (TMZ less effective in this subgroup):
- NCT06388733 - Niraparib (Zejula) vs Temozolomide in newly-diagnosed MGMT-unmethylated GBM (Phase 3; flagship trial for this hard-to-treat subgroup, asks whether a PARP inhibitor can replace TMZ when TMZ benefit is limited — the first PARP inhibitor Phase 3 in glioma, leveraging niraparib's documented BBB penetration)
- NCT05052957 - hSTAR: Chemoprotection with P140K-MGMT to allow TMZ dose escalation in MGMT-unmethylated GBM (Phase 2)
Immunotherapy + chemoradiation:
- NCT06556563 - EF-41/KEYNOTE D58: TTFields + TMZ + pembrolizumab vs TTFields + TMZ (Phase 3)
- NCT06991101 - Ruxolitinib (JAK1/2 inhibitor) + RT/TMZ vs RT/TMZ alone (Phase 2, randomized)
- NCT05664464 - Gabapentin (glutamate inhibitor) added to standard chemoradiation (Phase 1b/2)
Vaccine therapies:
- NCT06805305 - DOC1021 dendritic cell immunotherapy (Phase 2)
Radiation innovations:
- NCT07195591 - GammaTile placed at the time of GBM resection vs standard of care (Phase 3; immediate brachytherapy seeds at the tumor cavity at the time of surgery)
- NCT07459101 - MR-Linac guided adaptive radiotherapy for high-grade glioma (interventional, no phase listed)
- NCT05450744 - IPAX-2: 131I-TLX-101 targeted radiotherapy in newly diagnosed GBM (Phase 1)
Temozolomide modifications:
- NCT06419946 - Lomustine + TMZ/RT for MGMT-methylated GBM (Phase 3)
- NCT03213002 - CAPTEM: Capecitabine + temozolomide combination
Drug-delivery / vascular approaches:
- NCT05271240 - Repeated superselective intraarterial cerebral infusion (SIACI) of bevacizumab + TMZ/RT vs TMZ/RT alone in newly diagnosed GBM (Phase 3)
Other novel agents:
- NCT05669820 - Antisecretory factor for newly-diagnosed GBM (Phase 2/3)
- NCT07605364 - Mycophenolate mofetil added to RT + TMZ for advanced/newly-diagnosed GBM (Phase 2/3, opens summer 2026 — not yet recruiting, watch this one)
Platform / adaptive trials:
- NCT03970447 - GBM AGILE: Adaptive platform testing multiple agents simultaneously (Phase 2/3)
- NCT02977780 - INSIGhT: Biomarker-driven individualized therapy platform

Recurrent / Progressive GBM

After progression on standard chemoradiation — this is where the most novel approaches are being tested. Multiple new Phase 3 entrants in early 2026:

Phase 3 trials in recurrent / progressive disease:
- NCT05904119 - Lomustine with vs without reirradiation for first progression of GBM (Phase 3, randomized)
- NCT05902169 - Sonocloud-9 (BBB-opening ultrasound) + carboplatin vs standard-of-care chemotherapies (CCNU or TMZ) in recurrent GBM (Phase 3, focused ultrasound to enhance drug delivery)
- NCT06496971 - Avastin (bevacizumab) with or without microbubble-mediated focused ultrasound (NaviFUS) — pivotal study in recurrent GBM (Phase 3)
- NCT07100730 - TLX101-Tx (131I-iodinated targeted radiotherapy) + standard of care vs SOC alone in recurrent GBM (Phase 3)
CAR-T cell therapy:
- NCT07180927 - DLL3-targeted CAR-T for brain tumors (Phase 1/2)
- NCT06186401 - Anti-EGFRvIII synNotch CAR-T (E-SYNC; conditional activation that turns on an anti-EphA2/IL-13Rα2 CAR only inside the tumor, Phase 1)
Immunotherapy combinations:
- NCT06160206 - Retifanlimab + bevacizumab + hypofractionated RT in recurrent GBM (Phase 2)
Local / surgical therapies:
- NCT07145112 - LITT (laser interstitial thermal therapy) + lomustine for recurrent GBM (Phase 1)
Recurrent / progressive — MGMT-methylated:
- NCT05432804 - Selinexor + temozolomide for recurrent IDH-wildtype or MGMT-methylated GBM (Phase 1/2)

Showing selected notable trials. View all 285 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find glioblastoma clinical trials I'm eligible for?

Enter your GBM details into ClinTrialFinder — including IDH status, MGMT methylation, tumor grade, and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.

What types of glioblastoma trials are currently recruiting?

There are 285 recruiting interventional trials for glioblastoma in July 2026 including newly-diagnosed Phase 3s (niraparib vs TMZ for MGMT-unmethylated NCT06388733; GammaTile-at-resection vs SOC NCT07195591; lomustine + TMZ for MGMT-methylated NCT06419946; EF-41 / KEYNOTE-D58 TTFields + TMZ + pembrolizumab NCT06556563; intra-arterial bevacizumab + TMZ/RT NCT05271240), recurrent/progressive Phase 3s (lomustine + reirradiation NCT05904119; Sonocloud-9 + carboplatin BBB-opening NCT05902169; TLX101-Tx NCT07100730; Avastin + focused-ultrasound pivotal NCT06496971), CAR-T cell therapy (EGFRvIII, IL13Rα2, DLL3), checkpoint immunotherapy combinations, tumor vaccines, tumor treating fields (TTFields) with immunotherapy, and adaptive platform trials like GBM AGILE and INSIGhT.

Are there trials specifically for MGMT-unmethylated GBM?

Yes — MGMT-unmethylated patients benefit less from temozolomide alone, so several trials specifically target this population. The flagship Phase 3 is niraparib vs TMZ in newly-diagnosed MGMT-unmethylated GBM (NCT06388733). Other approaches include chemoprotection to allow higher TMZ doses (hSTAR NCT05052957). Sonocloud-9 BBB-opening + carboplatin (NCT05902169) is a Phase 3 for recurrent disease that can apply regardless of MGMT status.

What is the difference between IDH-wildtype and IDH-mutant glioblastoma?

Under the WHO 2021 CNS tumor classification, glioblastoma is defined as IDH-wildtype only. What used to be called "IDH-mutant glioblastoma" is now classified separately as IDH-mutant astrocytoma (typically grade 4) and is a different disease entity with different biology and trial options. Vorasidenib (Voranigo, FDA approved August 2024) is an IDH inhibitor for residual or recurrent grade 2 IDH-mutant glioma after surgery — it is not approved for and is not being studied as standard therapy for IDH-wildtype GBM. Knowing your IDH and MGMT status is essential for finding the right trials.

Find Glioblastoma Trials Matched to Your Situation

Enter your IDH status, MGMT methylation, and treatment history to get AI-matched trial results in minutes.